Janus Henderson Group PLC Aprea Therapeutics, Inc. Transaction History

Janus Henderson Group PLC

$187 Billion
Q3 2024

Shares

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2020 Feb 16, 2021	SELL	$4.92 - $30.67 $4.19 Million - $26.1 Million	-851,180 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$21.66 - $38.86 $2.02 Million - $3.63 Million	-93,414 Reduced 9.89%	851,180 $20.5 Million
Q2 2020 Aug 14, 2020	SELL	$25.47 - $39.69 $7.12 Million - $11.1 Million	-279,607 Reduced 22.84%	944,594 $36.6 Million
Q1 2020 May 14, 2020	SELL	$31.65 - $45.3 $18.6 Million - $26.6 Million	-586,658 Reduced 32.4%	1,224,201 $41.7 Million
Q4 2019 Feb 18, 2020	BUY	$18.94 - $49.53 $34.3 Million - $89.7 Million	1,810,859 New	1,810,859 $81 Million

Others Institutions Holding APRE

# of Institutions

2

Shares Held

899

Call Options Held

0

Put Options Held

0

Nbc Securities, Inc. Birmingham, AL

899
Shares

$2,688
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.